CN113440531A - Carbamazepine pharmaceutical composition and preparation method and application thereof - Google Patents
Carbamazepine pharmaceutical composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN113440531A CN113440531A CN202110771518.5A CN202110771518A CN113440531A CN 113440531 A CN113440531 A CN 113440531A CN 202110771518 A CN202110771518 A CN 202110771518A CN 113440531 A CN113440531 A CN 113440531A
- Authority
- CN
- China
- Prior art keywords
- carbamazepine
- parts
- pharmaceutical composition
- weight
- crospovidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a carbamazepine pharmaceutical composition which comprises, by weight, 80-120 parts of carbamazepine, 50-100 parts of hydroxypropyl cellulose, 50-100 parts of crospovidone, 10-50 parts of sodium dodecyl sulfate, 240-360 parts of cottonseed peptide and 160-240 parts of L-arabinose; the preparation method comprises mixing carbamazepine, hydroxypropyl cellulose, crospovidone, cottonseed peptide and L-arabinose uniformly, adding water for granulating, adding sodium dodecyl sulfate, mixing uniformly, and making into tablet. The invention can slowly release the medicine in vivo, and reduce the direct stimulation of carbamazepine to gastrointestinal tract, thereby reducing the side effect, especially the occurrence of serious gastrointestinal tract reaction, maintaining effective blood concentration, improving the compliance and safety of the medicine taking of patients, enabling the patients to be more tolerant and being beneficial to long-term treatment.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a carbamazepine pharmaceutical composition and a preparation method and application thereof.
Background
Carbamazepine is an antiepileptic drug, but overdose of carbamazepine can cause diarrhea in individual patients. When diarrhea occurs more than 5 times a day or bloody diarrhea occurs, it is generally necessary to reduce the drug dose or to stop carbamazepine immediately and treat it promptly. Generally, after the medicine is stopped, the treatment is difficult to smoothly carry out, thereby affecting the treatment effect. The main cause of diarrhea in patients receiving carbamazepine is the diarrhea complications due to direct inhibition or destruction of the intestinal mucosal cells by the drug: 1. the water electrolyte is disturbed. Large amounts of water and electrolytes are lost during diarrhea and, if not effectively replenished in time, water and electrolyte disturbances can occur to varying degrees, including low sodium, low potassium, low calcium, and low magnesium. 2. Anemia and malnutrition. The gastrointestinal tract is the only way for the human body to absorb nutrients, and after ingested food and other nutrients are digested (digested food) and decomposed in the gastrointestinal tract, a useful part is absorbed, and useless residues are discharged from the feces. In case of diarrhea, anemia and malnutrition may occur to different degrees due to loss of water electrolytes and poor appetite. It is manifested as emaciation, lassitude and weakness. 3. And (4) dehydrating. Due to the loss of body fluid and insufficient intake of diarrhea, the total amount of body fluid, especially extracellular fluid, is reduced, resulting in dehydration to varying degrees (light, medium, heavy). Pits, oliguria, lacrimation, dry skin mucosa, decreased elasticity, and even peripheral circulation changes due to insufficient blood volume. The severe cases may have pale complexion, cold sweating, restlessness and other manifestations. 4. Acidosis. When diarrhea is severe, acid poisoning may be caused by a large amount of alkaline substances lost in stool, which is mainly manifested as lethargy, pale complexion, food refusal, mental asthenia, etc. 5. And (5) secondary infection. After diarrhea, various infections, such as urinary tract infection, upper respiratory tract infection, otitis media and the like, can be generated after the general resistance is low. 6. Cardiovascular and cerebrovascular accidents. This is a non-negligible complication that causes death from acute diarrhea in the elderly. In diarrhea, a large amount of water and cations such as sodium, potassium, calcium, magnesium and the like in the body are discharged from the excrement, the human body is in a dehydration state due to water loss, the blood volume is reduced, the blood viscosity is increased, the blood flow is slow, thrombus is easily formed and blood vessels are blocked, angina and myocardial infarction are caused by coronary artery blockage, and ischemic stroke is caused by cerebrovascular blockage. Sodium, potassium, calcium and magnesium are important cations in the body, have the important function of maintaining the nerve conduction function and the heart rhythm besides maintaining the acid-base balance of blood, and can cause serious arrhythmia and sudden death when the deficiency occurs.
It is seen that diarrhea can reduce the quality of life of patients, and various infections may be secondary to the general resistance of patients with diarrhea. Long-term diarrhea can directly affect the body's deficiency of nutrients, causing anemia, malnutrition, and vitamin deficiency. Severe diarrhea causes dehydration, electrolyte disturbance and acidosis, which can cause serious damage to the body, and can endanger life if not rescued in time.
Disclosure of Invention
The object of the present invention, for example, includes providing a carbamazepine pharmaceutical composition effective in ameliorating side effects of the digestive tract caused by carbamazepine.
The invention also aims to provide a preparation method of the carbamazepine pharmaceutical composition, which is simple and can effectively improve side reactions of the digestive tract caused by carbamazepine.
The object of the present invention is also to provide a pharmaceutical composition of carbamazepine for use in the preparation of a medicament useful for reducing the side effects of diarrhea caused by carbamazepine.
In order to achieve the above purpose, the embodiment of the invention adopts the following technical scheme:
a pharmaceutical composition of carbamazepine comprises carbamazepine, hydroxypropyl cellulose, crospovidone, sodium dodecyl sulfate and cottonseed peptide.
Furthermore, the components of the carbamazepine pharmaceutical composition also comprise L-arabinose.
The carbamazepine pharmaceutical composition comprises, by weight, 80-120 parts of carbamazepine, 50-100 parts of hydroxypropyl cellulose, 50-100 parts of crospovidone, 10-50 parts of sodium dodecyl sulfate, 240-360 parts of cottonseed peptide and 160-240 parts of L-arabinose.
Further, the carbamazepine pharmaceutical composition comprises, by weight, 100 parts of carbamazepine, 75 parts of hydroxypropyl cellulose, 75 parts of crospovidone, 30 parts of sodium dodecyl sulfate, 300 parts of cottonseed peptide and 200 parts of L-arabinose.
The carbamazepine pharmaceutical composition may be in the form of a tablet.
A method for preparing carbamazepine pharmaceutical composition comprises mixing carbamazepine, hydroxypropyl cellulose, crospovidone, cottonseed peptide and L-arabinose uniformly, adding water for granulation, adding sodium dodecyl sulfate, mixing uniformly, and making into tablet.
The application of the carbamazepine pharmaceutical composition or the carbamazepine pharmaceutical composition prepared by the preparation method of the carbamazepine pharmaceutical composition in preparing a medicine for relieving side effects of diarrhea caused by carbamazepine.
The beneficial effects of the embodiment of the invention include:
in the embodiment, the dosage of the carbamazepine, the hydroxypropyl cellulose, the crospovidone, the sodium dodecyl sulfate, the cottonseed peptide and the L-arabinose is limited, so that the medicine can be slowly released in vivo, the direct stimulation of the carbamazepine to gastrointestinal tracts is reduced, the side effects, particularly the occurrence of severe gastrointestinal tract reactions, are reduced, the effective blood concentration is maintained, the compliance and the safety of the medicine use of a patient are improved, the patient can tolerate more easily, and the long-term treatment is facilitated. The carbamazepine medicine composition can promote gastrointestinal motility, promote food digestion and absorption, effectively improve side effects of digestive tracts caused by carbamazepine, and has a good effect of inhibiting diarrhea caused by carbamazepine.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The carbamazepine pharmaceutical composition of the present invention, its preparation method and use are described in detail below.
Carbamazepine is used as an antiepileptic drug, and has major side effects including gastrointestinal reactions such as diarrhea and the like when used in large doses.
Normal people defecate 1-2 times a day or 1 time every 2-3 days, and the nature of the excrement is normal.
The diarrhea patients not only have increased stool frequency, but also have changed properties, and have loose stools, watery stools and even bloody diarrhea.
The diarrhea is judged according to the principle that the water content of the collected feces is not less than 70 percent and the feces are not deformed. Diarrhea can be classified as grade 5 depending on severity. Grade 1, stool frequency increased <4 times/day, and excretion amount slightly increased; 2, the stool number is increased for 4-6 times per day, the discharged matter is moderately increased, and the daily life is not influenced; grade 3, stool frequency is increased by more than 7 times per day, incontinence needs 24 hours of intravenous fluid infusion, hospitalization is needed, and the amount of discharged substances is severely increased, so that daily life is influenced; grade 4: life threatening (e.g., hemodynamic failure); and 5, death.
The diarrhea mechanism mainly comprises: firstly, intestinal mucosa damage and water absorption disorder; ② the peristalsis of the intestine is strengthened, so that the contents in the intestine can be discharged quickly; ③ intestinal mucosa secretes intestinal juice and is hyperfunction.
Because the cell division and proliferation speed of the intestinal mucosa is fast, the intestinal mucosa is easy to be directly inhibited or destroyed by cytotoxic drugs, the atrophy of the intestinal mucosa is caused, the intestinal villi is shortened or stripped, the absorption area of the small intestine is reduced, and the integrity of the mucosa is destroyed, so that the digestive disorder, the digestion of cane sugar and maltose are insufficient, and the fermentation is carried out in the intestinal canal, thereby causing intestinal flatulence and intestinal spasm; absorbing obstacles; and thirdly, secretion is increased, and undigested sucrose and maltose increase the osmotic pressure of intestinal contents, so that a large amount of extracellular interstitial fluid permeates into the intestinal cavity. The main cause of diarrhea in patients receiving carbamazepine is due to direct inhibition or destruction of the intestinal mucosal cells by the drug, and is also associated with a number of other factors including secondary infections in the intestinal tract, emotional stress, etc.
In view of this, the embodiment of the invention provides a carbamazepine pharmaceutical composition, which comprises, by weight, 80-120 parts of carbamazepine, 50-100 parts of hydroxypropyl cellulose, 50-100 parts of crospovidone, 10-50 parts of sodium dodecyl sulfate and 10-50 parts of cottonseed peptide.
Further, the carbamazepine pharmaceutical composition also comprises 160-240 parts of L-arabinose.
Preferably, the carbamazepine pharmaceutical composition comprises, by weight, 100 parts of carbamazepine, 75 parts of hydroxypropyl cellulose, 75 parts of crospovidone, 30 parts of sodium dodecyl sulfate, 300 parts of cottonseed peptide and 200 parts of L-arabinose.
The dosage of the components is further limited, so that the medicine can be slowly released in vivo, and the direct stimulation of carbamazepine to gastrointestinal tracts is reduced, thereby reducing the occurrence of diarrhea, maintaining effective blood concentration, improving the compliance and safety of the medicine taking of patients, making the patients more tolerant and being beneficial to long-term treatment.
In a second aspect, the embodiment of the present invention further provides a preparation method of a carbamazepine pharmaceutical composition, which includes the following steps:
1. mixing carbamazepine, hydroxypropyl cellulose and crospovidone uniformly, adding water and granulating.
The method specifically comprises the following steps: firstly, smashing carbamazepine to 100-120 meshes, placing the carbamazepine, the crospovidone, the hydroxypropyl cellulose, the starch, the cottonseed peptide and the L-arabinose into a wet granulator, mixing, adding a proper amount of purified water, and granulating. Wet granulating by using a swing granulator, wherein the mesh number of a screen is 12-14 meshes. And (3) placing the wet granules in a high-efficiency boiling dryer, preheating for 10min at the air inlet temperature of 60-70 ℃, drying at room temperature, and controlling the moisture of the granules to be 2-6%. And (4) granulating the dried granules in a swing granulator, wherein the mesh number of a screen is 16-18 meshes. And finishing the granules for later use.
2. Then adding sodium dodecyl sulfate, mixing uniformly and preparing into tablets. Adding sodium dodecyl sulfate, mixing in mixer. Then, the preparation is carried out to prepare tablets. When the tablet is prepared, the filling amount, the tablet thickness and the tablet press speed are adjusted, the tablet hardness is controlled to be 70-90N, the standard tablet weight is converted according to the content of intermediate particles, and the tablet weight difference is controlled.
3. Preparation of a coating agent: adding a proper amount of purified water into a liquid preparation barrel, starting a stirring paddle to stir, enabling the liquid surface to form a vortex, scattering gastric-soluble film coating powder on the liquid surface of the vortex at a constant speed, and continuously stirring for more than 1 hour, wherein the dosage of the coating powder is 2.0-3.0% of the weight of the tablet, and the concentration of the coating agent is 10-15%. Adjusting air inlet and outlet quantity, controlling the air outlet temperature to be 40-50 ℃, enabling the negative pressure in the pan to be 2-5 pa, adding the plain tablets into a coating pan, taking out the pan at 2 revolutions per minute after the temperature of the plain tablets is preheated to 35-40 ℃ and the optimal distance between a spray gun and a tablet surface is 26-30 cm, and adjusting the gun head of the spray gun to the position 1/3 on the inclined surface of the tablet layer to start spraying liquid. In the coating process, the spraying air pressure and the spraying angle of the spray gun are adjusted to be consistent as much as possible, and the rotating speed of the peristaltic pump is properly adjusted, so that an ideal atomizing state required by the process can be achieved. After the film coating liquid is sprayed, cooling the film coated tablet by using air exhaust, and packaging by using aluminum plastic.
In the present embodiment, after wet granulation, wet granulation and drying are performed, and then dry granulation is performed, and the mesh sizes of the wet granulation and the dry granulation are controlled to be 12 to 14 mesh and 16 to 18 mesh, respectively, so that the uniformity of the finally obtained granules is better.
In another aspect, the embodiments of the present invention further provide a use of a carbamazepine pharmaceutical composition in the preparation of a medicament for alleviating side effects of diarrhea caused by carbamazepine.
The carbamazepine pharmaceutical compositions of the present invention, as well as methods of preparation and use thereof, are further illustrated below with reference to the examples.
Example 1
The embodiment provides a carbamazepine pharmaceutical composition, which is prepared by the following steps:
1. preparing materials: 120g of carbamazepine, 50g of hydroxypropyl cellulose, 100g of crospovidone, 100g of sodium dodecyl sulfate and 240g of cottonseed peptide.
2. And (3) granulating: pulverizing carbamazepine to 120 meshes; placing carbamazepine, hydroxypropyl cellulose, starch and crospovidone in a wet granulator, mixing for 5 minutes, adding a proper amount of purified water, and granulating for 2 minutes. Wet granulating with a rocking granulator, wherein the mesh number of the screen is 12. Placing the wet granules in a high-efficiency boiling dryer, preheating the dryer for 10min by using wind with the temperature of 70 ℃, and then drying at room temperature. The moisture of the granules is controlled to be about 2 percent. And (4) granulating the dried granules in a swing granulator, wherein the mesh number of a screen is 16. And finishing the granules for later use. Then adding sodium dodecyl sulfate, mixing uniformly and preparing into tablets.
Example 2
The embodiment provides a carbamazepine pharmaceutical composition, which is prepared by the following steps:
1. preparing materials: 80g of carbamazepine, 100g of hydroxypropyl cellulose, 50g of crospovidone, 50 parts of lauryl sodium sulfate, 360g of cottonseed peptide and 20g of gastric-soluble film coating premix.
2. And (3) granulating: pulverizing carbamazepine to 100 meshes; placing carbamazepine, hydroxypropyl cellulose, starch and crospovidone in a wet granulator, mixing for 6 minutes, adding a proper amount of purified water, and granulating for 1 minute. Wet granulating with a rocking granulator, wherein the mesh number of the screen is 14. Placing the wet granules in a high-efficiency boiling dryer, preheating the dryer for 15min by using air with the temperature of 60 ℃, and then drying at room temperature. The moisture of the granules is controlled to be about 6 percent. And (4) granulating the dried granules in a swing granulator, wherein the mesh number of a screen is 18. And finishing the granules for later use. Then adding sodium dodecyl sulfate, mixing uniformly and preparing into tablets.
3. Coating: adding appropriate amount of purified water into the liquid preparation barrel, starting stirring slurry to stir, making the liquid surface form vortex, scattering gastric-soluble film coating powder on the vortex liquid surface at constant speed, and continuously stirring for more than 1 hour, wherein the concentration of the coating agent is 10%. Adjusting air inlet and outlet quantity, controlling the air outlet temperature to be 50 ℃, enabling the negative pressure in the pan to be 5pa, adding the plain film into the coating pan, taking out the pan at 2 revolutions per minute when the temperature of the plain film is preheated to 40 ℃ and the optimal distance between the spray gun and the film surface is 26cm, and adjusting the gun head of the spray gun to the upper part 1/3 of the inclined surface of the film layer to start spraying liquid. In the coating process, the spraying air pressure and the spraying angle of the spray gun are adjusted to be consistent as much as possible, and the rotating speed of the peristaltic pump is properly adjusted, so that an ideal atomizing state required by the process can be achieved. After the film coating liquid is sprayed, cooling the film coated tablets by using air exhaust, and packaging the film coated tablets by aluminum plastic to obtain the tablets of the carbamazepine pharmaceutical composition.
Example 3
The embodiment provides a carbamazepine pharmaceutical composition, which is prepared by the following steps:
1. preparing materials: 100g of carbamazepine, 75g of hydroxypropyl cellulose, 75g of crospovidone, 30g of lauryl sodium sulfate, 300g of cottonseed peptide and 20g of gastric-soluble film coating premix.
2. And (3) granulating: pulverizing carbamazepine to 100 meshes; placing carbamazepine, cottonseed peptide L-arabinose, hydroxypropyl cellulose, starch and crospovidone in a wet granulator, mixing for 5 minutes, adding a proper amount of purified water, and granulating for 1 minute. Wet granulating with a rocking granulator, wherein the mesh number of the screen is 14. Placing the wet granules in a high-efficiency boiling dryer, preheating the dryer for 10min by using air with the temperature of 65 ℃, and then drying at room temperature. The moisture of the particles is controlled to be about 2-6%. And (4) granulating the dried granules in a swing granulator, wherein the mesh number of a screen is 18. And finishing the granules for later use. Then adding sodium dodecyl sulfate, mixing uniformly and preparing into plain tablets.
3. Coating: adding appropriate amount of purified water into the liquid preparation barrel, starting stirring slurry to stir, making the liquid surface form vortex, scattering gastric-soluble film coating powder on the vortex liquid surface at constant speed, and stirring for more than 1 hr to obtain coating agent with concentration of 12%. Adjusting air inlet and outlet quantity, controlling the air outlet temperature to be 45 ℃, enabling the negative pressure in the pan to be 3pa, adding the plain film into the coating pan, taking the plain film out at 2 revolutions per minute when the temperature of the plain film is preheated to 35 ℃ and the optimal distance between the spray gun and the film surface is 28cm, and adjusting the gun head of the spray gun to the upper part 1/3 of the inclined surface of the film layer to start spraying liquid. In the coating process, the spraying air pressure and the spraying angle of the spray gun are adjusted to be consistent as much as possible, and the rotating speed of the peristaltic pump is properly adjusted, so that an ideal atomizing state required by the process can be achieved. After the film coating liquid is sprayed, cooling the film coated tablets by using air exhaust, and packaging the film coated tablets by aluminum plastic to obtain the tablets of the carbamazepine pharmaceutical composition.
Examples 4 to 6
The preparation method of the carbamazepine pharmaceutical composition provided in examples 4-6 is substantially the same as that of example 3, and the difference is that L-arabinose is mainly added.
In example 4, the components of the carbamazepine pharmaceutical composition include 100g of carbamazepine, 75g of hydroxypropyl cellulose, 75g of crospovidone, 30g of sodium dodecyl sulfate, 300g of cottonseed peptide, 160g of L-arabinose and 20g of a gastric-soluble film coating premix.
In example 5, the components of the carbamazepine pharmaceutical composition include 100g of carbamazepine, 75g of hydroxypropyl cellulose, 75g of crospovidone, 30g of sodium dodecyl sulfate, 300g of cottonseed peptide, 240g of L-arabinose and 20g of a gastric-soluble film coating premix.
In example 6, the components of the carbamazepine pharmaceutical composition include 100g of carbamazepine, 75g of hydroxypropyl cellulose, 75g of crospovidone, 30g of sodium dodecyl sulfate, 300g of cottonseed peptide, 200g of L-arabinose and 20g of gastric-soluble film coating premix.
Example 7
The L-arabinose in example 6 was replaced with cottonseed peptide, and the composition was prepared in the same manner as in example 3.
Example 8
The cottonseed peptide in example 6 was replaced with L-arabinose and the composition was prepared in the same manner as in example 3.
Comparative examples 1 to 8
The cottonseed peptide and the L-arabinose in the examples 1 to 8 were replaced by starch, and the preparation methods of the compositions were not changed as comparative examples 1 to 8, respectively.
First, animal experiment
The following will evaluate the effect of the pharmaceutical compositions provided in examples 1 to 8 and comparative examples 1 to 8 of the present invention in improving the digestive tract reaction caused by carbamazepine, in combination with animal experiments.
Effect of the composition of the invention on diarrhea in domestic Pigeon
160 domestic pigeons with the weight of 200-300 g are selected, the male pigeons and the female pigeons are half in half, the domestic pigeons are randomly divided into 16 groups, and each group comprises 10 pigeons. Before the experiment, the pigeon does not have to be fasted for 24 hours, the pigeon is administrated and each composition (examples 1-8 and comparative examples 1-8) is intragastrically administrated, the amount of carbamazepine is 100 mg/pigeon, the diarrhea frequency and the number of the pigeon in 12 hours after the administration are recorded, and the experimental results are compared among groups and are shown in table 1:
TABLE 1 diarrhea in domestic pigeon
In conclusion, the pharmaceutical composition provided by the invention can promote gastrointestinal motility and promote food digestion and absorption, can effectively improve side effects of the digestive tract caused by carbamazepine, and has a good effect of inhibiting diarrhea caused by carbamazepine.
The details which are not described in the present invention are the common general knowledge which can be selected by the ordinary skilled person in the art. Although the invention has been described in detail hereinabove with respect to specific embodiments thereof, it will be apparent to those skilled in the art that modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. A carbamazepine pharmaceutical composition is characterized by comprising carbamazepine, hydroxypropyl cellulose, crospovidone, sodium dodecyl sulfate and cottonseed peptide.
2. The carbamazepine pharmaceutical composition of claim 1, wherein the component further includes L-arabinose.
3. The carbamazepine pharmaceutical composition according to claim 2, which comprises 80-120 parts by weight of carbamazepine, 50-100 parts by weight of hydroxypropyl cellulose, 50-100 parts by weight of crospovidone, 10-50 parts by weight of sodium dodecyl sulfate, 240-360 parts by weight of cottonseed peptide and 160-240 parts by weight of L-arabinose.
4. The carbamazepine pharmaceutical composition according to claim 2, characterized by comprising, by weight, 100 parts of carbamazepine, 75 parts of hydroxypropylcellulose, 75 parts of crospovidone, 30 parts of sodium lauryl sulfate, 300 parts of cottonseed peptide, and 200 parts of L-arabinose.
5. The carbamazepine pharmaceutical composition of claim 3, wherein the carbamazepine pharmaceutical composition is a tablet.
6. A process for preparing the carbamazepine pharmaceutical composition of claim 5 which comprises mixing the carbamazepine, the hydroxypropylcellulose, the crospovidone, the cottonseed peptide and the L-arabinose uniformly, adding water to granulate, then adding the sodium lauryl sulfate, mixing uniformly and tabletting.
7. The method of claim 6, wherein the granulation comprises wet granulation followed by wet granulation, sieving through a 12-14 mesh sieve, followed by drying until the moisture content of the granules is 2% -6%, and dry granulation followed by sieving through a 16-18 mesh sieve.
8. The process for preparing a carbamazepine pharmaceutical composition according to claim 7 characterised in that the granules are placed in a dryer and, before drying, the dryer is preheated for 10-15 min with air at a temperature of 60-70 ℃ and then dried at room temperature.
9. The preparation method of the carbamazepine pharmaceutical composition according to claim 6, characterized in that the components comprise 20-30 parts by weight of the coating agent, the coating powder is prepared into the coating agent with the concentration of 10-15%, the plain tablets are preheated to 35-40 ℃, the coating agent is sprayed on the surfaces of the plain tablets, and then the tablets are cooled.
10. Use of a carbamazepine pharmaceutical composition according to any one of claims 1 to 5 or a process for the preparation of a carbamazepine pharmaceutical composition according to any one of claims 6 to 9 in the manufacture of a medicament for reducing the side effects of diarrhea caused by carbamazepine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771518.5A CN113440531A (en) | 2021-07-08 | 2021-07-08 | Carbamazepine pharmaceutical composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771518.5A CN113440531A (en) | 2021-07-08 | 2021-07-08 | Carbamazepine pharmaceutical composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113440531A true CN113440531A (en) | 2021-09-28 |
Family
ID=77815376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110771518.5A Pending CN113440531A (en) | 2021-07-08 | 2021-07-08 | Carbamazepine pharmaceutical composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113440531A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090143362A1 (en) * | 2007-12-04 | 2009-06-04 | Barabde Umesh Vinayakrao | Carbamazepine formulations |
| CN101647784A (en) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | Carbamazepine sustained-release tablet and preparation method thereof |
| CN112168792A (en) * | 2020-09-29 | 2021-01-05 | 江苏鹏鹞药业有限公司 | Carbamazepine tablet and preparation method thereof |
-
2021
- 2021-07-08 CN CN202110771518.5A patent/CN113440531A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090143362A1 (en) * | 2007-12-04 | 2009-06-04 | Barabde Umesh Vinayakrao | Carbamazepine formulations |
| CN101647784A (en) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | Carbamazepine sustained-release tablet and preparation method thereof |
| CN112168792A (en) * | 2020-09-29 | 2021-01-05 | 江苏鹏鹞药业有限公司 | Carbamazepine tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961469A (en) | Traditional Chinese medicinal composition and application thereof, healthy product and preparation method thereof | |
| CN109044988B (en) | Metformin hydrochloride pharmaceutical composition and preparation method and application thereof | |
| CN101007071A (en) | Traditional Chinese medicine for treating acute and chronic gastroenteritis and bacterial dysentery and its processing technology | |
| WO2021164523A1 (en) | Akkermansia muciniphila composition | |
| CN102552871B (en) | A kind of tannalbin yeast chewable tablet and production method thereof | |
| CN113440531A (en) | Carbamazepine pharmaceutical composition and preparation method and application thereof | |
| CN106692744A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN109045034B (en) | Moxifloxacin hydrochloride pharmaceutical composition and preparation method and application thereof | |
| CN116139257A (en) | Traditional Chinese medicine formula for treating postpartum hypogalactia of sow and preparation method thereof | |
| CN102755310A (en) | Composition drug preparation containing levodopa | |
| CN1762347A (en) | Andrographolide preparation and its production method | |
| WO2023138173A1 (en) | Chitosan oligosaccharide enteric dripping pill and application thereof in preparing non-alcoholic fatty liver disease drug | |
| CN111821266B (en) | Taurine sustained-release composition and preparation method thereof | |
| CN108904495B (en) | Levetiracetam pharmaceutical composition and preparation method and application thereof | |
| CN111759849B (en) | Anti-angina pectoris pharmaceutical composition and preparation method and application thereof | |
| CN101190185A (en) | Alkaline drug enteric preparation and preparation method thereof | |
| CN103655585A (en) | Gastrodin controlled release preparation and preparation method thereof | |
| CN103800290A (en) | Glucosamine hydrochloride pellet preparation and preparation method thereof | |
| CN106387904A (en) | Composition, preparation method of composition, preparation and use | |
| CN101703475A (en) | Chondroitin sulfate pellet and preparation method thereof | |
| CN110547462A (en) | White asparagus lettuce and oat meal replacement powder and preparation method thereof | |
| CN101129786B (en) | Pharmaceutical composition used for ulcer of upper digestive tract | |
| CN112568430A (en) | A composition comprising semen Phaseoli vulgaris and fructus Momordicae Charantiae for reducing weight and fat, and its preparation method | |
| CN100531741C (en) | Magnesium isoglycyrrhetate oral preparation and its making method | |
| CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210928 |